Ikena Oncology Inc (IKNA)
1.42
+0.02
(+1.43%)
USD |
NASDAQ |
May 17, 16:00
1.43
+0.01
(+0.70%)
After-Hours: 20:00
Ikena Oncology Enterprise Value: -88.34M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 17, 2024 | -88.34M |
May 16, 2024 | -89.79M |
May 15, 2024 | -92.92M |
May 14, 2024 | -93.17M |
May 13, 2024 | -93.65M |
May 10, 2024 | -95.10M |
May 09, 2024 | -92.20M |
May 08, 2024 | -91.24M |
May 07, 2024 | -89.31M |
May 06, 2024 | -94.13M |
May 03, 2024 | -93.65M |
May 02, 2024 | -93.65M |
May 01, 2024 | -94.61M |
April 30, 2024 | -93.65M |
April 29, 2024 | -93.17M |
April 26, 2024 | -94.61M |
April 25, 2024 | -94.13M |
April 24, 2024 | -95.10M |
April 23, 2024 | -92.20M |
April 22, 2024 | -94.61M |
April 19, 2024 | -93.17M |
April 18, 2024 | -96.54M |
April 17, 2024 | -97.51M |
April 16, 2024 | -96.06M |
April 15, 2024 | -95.58M |
Date | Value |
---|---|
April 12, 2024 | -93.17M |
April 11, 2024 | -90.75M |
April 10, 2024 | -96.54M |
April 09, 2024 | -93.17M |
April 08, 2024 | -93.65M |
April 05, 2024 | -92.20M |
April 04, 2024 | -91.72M |
April 03, 2024 | -92.92M |
April 02, 2024 | -92.92M |
April 01, 2024 | -90.27M |
March 28, 2024 | -106.94M |
March 27, 2024 | -108.39M |
March 26, 2024 | -108.39M |
March 25, 2024 | -105.97M |
March 22, 2024 | -104.04M |
March 21, 2024 | -103.08M |
March 20, 2024 | -100.42M |
March 19, 2024 | -103.08M |
March 18, 2024 | -103.08M |
March 15, 2024 | -99.70M |
March 14, 2024 | -105.01M |
March 13, 2024 | -107.42M |
March 12, 2024 | -108.39M |
March 11, 2024 | -105.01M |
March 08, 2024 | -98.25M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-132.75M
Minimum
Nov 09 2023
944.32M
Maximum
Mar 26 2021
55.58M
Average
1.032M
Median
Apr 05 2022
Enterprise Value Benchmarks
NovaBay Pharmaceuticals Inc | 5.156M |
Palatin Technologies Inc | 22.26M |
iBio Inc | 16.77M |
Theriva Biologics Inc | -8.901M |
Oragenics Inc | 8.862M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -16.15M |
Total Expenses (Quarterly) | 15.64M |
EPS Diluted (Quarterly) | -0.33 |
Earnings Yield | -109.8% |
Normalized Earnings Yield | -125.74 |